Any experiences with using this small molecule GLP-1, and how it compares to systemic GLP-1's.I am familiar with the literature comparisons, but am curious about anecdotal data and reports?

Nuanced question. Dihydroberberine or Metformin when considering glucose/lipid modulating effects for longevity around a protocol involving strength training, HIIT, and some zone 2. I know the research tends to describe Metformin being more detrimental to exercise adaptations, but is this known similarly with DHB? I know Dr. Seeds is not a fan of Metformin d/t some negative mitochondrial changes that can occur. @Anthony Castore

With Red light therapy, is it better to utilize in the evening before bed, or upon waking? For more systemic effects, not localized healing.

Sleep isn’t passive recovery it’s a cellular recalibration.And if you're not sleeping deeply, your mitochondria, immune system, and brain aren’t clearing debris, regulating inflammation, or consolidating memory efficiently. Enter: Sleep peptides—not sedatives, but neurobiological modulators that repair signaling patterns upstream of symptoms like fatigue, anxiety, poor REM, and sleep fragmentation. Let’s break down the 3 most compelling tools: 1. DSIP (Delta Sleep-Inducing Peptide) - Primary action: Normalizes sleep architecture and promotes deep non-REM sleep - Mechanism: Reduces corticotropin-releasing hormone (CRH), dampens HPA axis hyperactivity, improves hypothalamic GABA tone - Bonus: Acts on mitochondrial protection and glymphatic clearance - When to use: Difficulty staying asleep, nervous system overdrive, parasympathetic insufficiency 2. Semax - Primary action: Neuroprotective and cognitive-enhancing, especially under stress - Mechanism: Boosts BDNF, modulates dopamine/serotonin, reduces neuroinflammation via NRF2 and antioxidant pathways - Bonus: Promotes resilience under oxidative stress - When to use: Brain fog, mood swings, post-infection fatigue, circadian mismatch 3. Epitalon (Epithalamin analog) - Primary action: Normalizes circadian rhythm via pineal gland restoration - Mechanism: Increases melatonin, reduces oxidative damage, supports telomerase activity, improves pineal peptide signaling - Bonus: Supports SIRT1 and FOXO3a longevity genes - When to use: Chronically poor sleep timing, aging-related rhythm disruption, neuroinflammation Big Picture:These aren’t “knock-you-out” tools like sedatives.They restore signaling fidelity—allowing your body to re-enter deep sleep states and modulate inflammatory and redox pathways during sleep. Want to try them? Stacking depends on your redox state, inflammation load, and circadian integrity. Drop a comment and share your favorite sleep stack.

Every industry has defining moments the ones that separate hype from principle and reveal who’s truly here for the long game. This is one of those moments for ours, and I want to be completely transparent about where we stand. Biomed Industries is the company credited with discovering Bioglutide (NA-931) and developing it as a next-generation GLP-based compound. Our raw materials came from the same supplier Biomed reportedly uses. Recently, serious accusations have surfaced against Biomed claims of fraudulent data, lack of publicly verifiable sequence information, and the absence of a disclosed CAS number or molecular structure. The accuser has raised valid scientific concerns that deserve to be addressed. At the same time, these allegations are new, and Biomed has not yet had the opportunity to publicly respond. That’s why we are pausing not panicking. Even in moments like this, our safeguards remain strong. We can fully document purity through HPLC and LC-MS, confirm sterility and endotoxin levels, and provide verified Certificates of Analysis. However, without a public reference structure or sequence, no lab including ours can confirm 100% molecular identity. We can verify that a compound is clean, sterile, and potent, but we can’t compare it to a molecule that’s never been fully published. To give some context, CB4211 is a great example of how innovation often moves faster than public documentation. This compound, developed for mitochondrial health and metabolic optimization, has been prescribed by physicians and compounded by pharmacies despite its structure, sequence, and CAS never being publicly released. That doesn’t make it ineffective or illegitimate it simply illustrates that, just like Bioglutide, the available data can only go so far. In both cases, these products are sourced, tested, and manufactured to the highest standards, with thorough purity and safety testing but without full structural transparency. That means identity and uniqueness are established through trust, testing, and outcomes rather than public disclosure. For all we know, CB4211 could be a more advanced form or reformulated analog of MOTS-c—or perhaps just a more expensive version under a new label. Until formal sequencing or patent releases are made public, no one can say for sure. This doesn’t discredit its value; it simply reminds us that in early-stage biotech, certainty often trails behind discovery. That’s why rigorous testing, ethical sourcing, and open communication about what is known and what isn’t are so vital.